ASH: Merck's Keytruda nabs speedy FDA review in non-Hodgkin lymphoma

Keytruda
The priority review designation is a boost for Keytruda, which had some setbacks this summer. (Image: Merck)

ATLANTAMerck’s quest to move Keytruda further into blood cancers hit a snag over the summer, but now, it’s back on track.

The FDA has accepted the New Jersey drugmaker’s application for the immuno-oncology star in previously treated primary mediastinal large B-cell lymphoma (PMBCL), a form of non-Hodgkin lymphomaand it’s bestowed its priority review tag to the application to boot.

The designation lines up a speedy review for Keytruda as regulators sift through results from Merck’s Keynote-170 trial, which showed Keytruda could provoke a response in 41% of patients and a complete response in 24% of them. The data were presented Sunday at the American Society of Hematology annual meeting.

Cambrex Webinar

Understanding the Importance of Crystallization Processes to Avoid Unnecessary Cost, Risk and Development Delays

Wednesday, May 27, 2020 | 10am ET / 7am PT

A well-developed crystallization process can produce suitable particles that can facilitate consistent filtration, drying and formulation of the API and allow confident and reliable manufacturing of the final drug product, while avoiding unnecessary cost, risk and development delays.

RELATED: Merck's Keytruda nabs first blood-cancer nod, but rare cancer decision has to wait

If Merck can snag a go-ahead in PMBCL, it’ll be Keytruda’s second approval in blood cancer. Back in March, it won a green light to treat patients with refractory classical Hodgkin lymphoma (cHL), or those who have relapsed after three or more prior treatment lines.

Lately, though, it’s had a tougher time; in July, after reviewing deaths in two Keytruda trials, the FDA put a pair of Merck studies on hold and stopped Keytruda dosing in a third. The moves dashed the drugmaker’s hopes for combining its checkpoint inhibitor with Celgene giants Pomalyst and Revlimid.

Keytruda has gone on a tear this year, grabbing a series of FDA blessings in areas including front-line lung cancer and bladder cancer. Most recently, it nabbed a stomach-cancer OK in September.

Suggested Articles

BMS' Opdivo and Yervoy only just won their first approval in previously untreated metastatic NSCLC, but the pair is already making it two.

Wrapping up the legal battle at $10 billion would be a win for Bayer, as it has lost $30 billion in market value since the Monsanto buyout.

Takeda’s Alunbrig has arrived in previously untreated, ALK-positive NSCLC. But there’s plenty of competition waiting to greet it at the door.